TW202038964A - 組合療法 - Google Patents

組合療法 Download PDF

Info

Publication number: TW202038964A
Authority: TW; Taiwan
Prior art keywords: pharmaceutically acceptable; acceptable salt; inhibitor; cancer; combination
Prior art date: 2018-12-20

Application number

TW108147073A

Other languages

English (en)

Chinese (zh)

Inventor

吉歐丹諾卡伯尼吉洛

Original Assignee

瑞士商諾華公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-12-20

Filing date

2019-12-20

Publication date

2020-11-01

2019-12-20 Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司

2020-11-01 Publication of TW202038964A publication Critical patent/TW202038964A/zh

Links

UEPXBTCUIIGYCY-UHFFFAOYSA-N Cc(ccc(NC(c1cc(C(F)(F)F)ncc1)=O)c1)c1-c1cc(OCCO)nc(N2CCOCC2)c1 Chemical compound Cc(ccc(NC(c1cc(C(F)(F)F)ncc1)=O)c1)c1-c1cc(OCCO)nc(N2CCOCC2)c1 UEPXBTCUIIGYCY-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

TW108147073A 2018-12-20 2019-12-20 組合療法 TW202038964A (zh)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US201862782767P	2018-12-20	2018-12-20
US62/782,767		2018-12-20
US201962793128P	2019-01-16	2019-01-16
US62/793,128		2019-01-16

Publications (1)

Publication Number	Publication Date
TW202038964A true TW202038964A (zh)	2020-11-01

Family

ID=69165429

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW108147073A TW202038964A (zh)	2018-12-20	2019-12-20	組合療法

Country Status (12)

Country	Link
EP (1)	EP3897591A1 (ja)
JP (1)	JP2022514056A (ja)
KR (1)	KR20210105388A (ja)
CN (1)	CN113453671A (ja)
AU (1)	AU2019407159A1 (ja)
BR (1)	BR112021011699A2 (ja)
CA (1)	CA3123510A1 (ja)
CL (1)	CL2021001623A1 (ja)
IL (1)	IL283937A (ja)
MX (1)	MX2021007477A (ja)
TW (1)	TW202038964A (ja)
WO (1)	WO2020128878A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2021229439A1 (en) *	2020-05-12	2021-11-18	Novartis Ag	Therapeutic combinations comprising a craf inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR091876A1 (es) *	2012-07-26	2015-03-04	Novartis Ag	Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
US9242969B2 (en)	2013-03-14	2016-01-26	Novartis Ag	Biaryl amide compounds as kinase inhibitors
WO2017037587A1 (en) *	2015-08-28	2017-03-09	Novartis Ag	Combination of ribociclib and dabrafenib for treating or preventing cancer
FI3618875T3 (fi)	2017-05-02	2023-07-04	Novartis Ag	Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito

2019
- 2019-12-18 EP EP19836553.8A patent/EP3897591A1/en not_active Withdrawn
- 2019-12-18 CN CN201980092575.1A patent/CN113453671A/zh active Pending
- 2019-12-18 MX MX2021007477A patent/MX2021007477A/es unknown
- 2019-12-18 AU AU2019407159A patent/AU2019407159A1/en not_active Abandoned
- 2019-12-18 CA CA3123510A patent/CA3123510A1/en active Pending
- 2019-12-18 BR BR112021011699-0A patent/BR112021011699A2/pt not_active Application Discontinuation
- 2019-12-18 JP JP2021535501A patent/JP2022514056A/ja active Pending
- 2019-12-18 WO PCT/IB2019/060987 patent/WO2020128878A1/en unknown
- 2019-12-18 KR KR1020217022093A patent/KR20210105388A/ko not_active Application Discontinuation
- 2019-12-20 TW TW108147073A patent/TW202038964A/zh unknown
2021
- 2021-06-13 IL IL283937A patent/IL283937A/en unknown
- 2021-06-17 CL CL2021001623A patent/CL2021001623A1/es unknown

Also Published As

Publication number	Publication date
IL283937A (en)	2021-07-29
EP3897591A1 (en)	2021-10-27
MX2021007477A (es)	2021-08-05
WO2020128878A1 (en)	2020-06-25
AU2019407159A1 (en)	2021-07-15
CN113453671A (zh)	2021-09-28
CA3123510A1 (en)	2020-06-25
KR20210105388A (ko)	2021-08-26
CL2021001623A1 (es)	2022-02-11
JP2022514056A (ja)	2022-02-09
BR112021011699A2 (pt)	2021-09-08

Publication	Publication Date	Title
JP7309614B2 (ja)	2023-07-18	組み合わせ療法
TWI607754B (zh)	2017-12-11	醫藥組合
JP2019532051A (ja)	2019-11-07	Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ
US20140348819A1 (en)	2014-11-27	Methods of Treating Cancer
TW202133857A (zh)	2021-09-16	用於乳癌治療之組合療法
TW202038964A (zh)	2020-11-01	組合療法
KR20220008870A (ko)	2022-01-21	노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
TW202342047A (zh)	2023-11-01	使用經取代之嘧啶-4(3h)-酮及索托拉西布(sotorasib)之組合療法
TW202140029A (zh)	2021-11-01	用於治療ｂｒａｆ突變型ｎｓｃｌｃ的包含ｒａｆ抑制劑之治療組合
RU2815400C2 (ru)	2024-03-14	Комбинированная терапия
CN115364231B (zh)	2023-11-17	一种增强ezh2抑制剂抗肿瘤作用的药物组合物及其用途
JP2023525100A (ja)	2023-06-14	Ｃｒａｆ阻害剤を含む治療的組み合わせ
TW202404599A (zh)	2024-02-01	使用經取代之嘧啶-4(3h)-酮及納武單抗(nivolumab)之組合療法